Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 30, 2022 - Issue 6
Submit an article Journal homepage
334
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Efficacy of Biosimilar Adalimumab in the Treatment of Behçet’s Uveitis

Masoud Soheiliana Ophthalmology Department and Ophthalmic Research Center, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, IranCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7508-426X
, MDORCID Icon,
Nazanin Ebrahimiadibb Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Science, Tehran, IranORCID Iconhttps://orcid.org/0000-0002-2058-9225
, MDORCID Icon,
Alireza Hedayatfarc Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, IranORCID Iconhttps://orcid.org/0000-0002-5667-5379
, MDORCID Icon,
Maryam Hosseinid Eye Research Center, Mashhad University of Medical Sciences, Tehran, IranORCID Iconhttps://orcid.org/0000-0002-4233-9243
, MDORCID Icon,
Mohammad Zareie Retina Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IranORCID Iconhttps://orcid.org/0000-0002-8808-2244
, MDORCID Icon &
Nassim Anjidanif Medical Department, Orchid Pharmed Company, Tehran, Iran
, PharmD
Pages 1495-1500 | Received 18 Aug 2020, Accepted 01 Mar 2021, Published online: 07 Apr 2021

References

  • Feigenbaum A. Description of Behçet’s syndrome in the Hippocratic third book of endemic diseases. Br J Ophthalmol. June, 1956;40(6):355. doi:10.1136/bjo.40.6.355.
  • Behget H. Uber rezidivierende, Aphthose, durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr. 1937;105:1152–1157.
  • Mutlu S, Scully C. The person behind the eponym: Hulûsi Behcet (1889–1948). J Oral Pathol Med. August, 1994;23(7):289–290. doi:10.1111/j.1600-0714.1994.tb00063.x.
  • Davatchi F, Jamshidi AR, Banihashemi AT, et al. Prevalence of Behcet’s disease in Iran: a WHO‐ILAR COPCORD stage I study. APLAR J Rheumatol. September, 2007;10(3):239–243. doi:10.1111/j.1479-8077.2007.00295.x.
  • Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. June 1, 2018;77(6):808–818. doi:10.1136/annrheumdis-2018-213225.
  • Hatemi G, Silman A, Bang D, et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis. October 1, 2009;68(10):1528–1534. doi:10.1136/ard.2008.087957.
  • Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. December 1, 2008;67(12):1656–1662. doi:10.1136/ard.2007.080432.
  • Weichsler B, Davatchi F, Lehner T, et al. Criteria for diagnosis of Behçet’s disease. Lancet (British edition). 1990;335(8697):1078–1080.
  • Martín-Varillas JL, Calvo-Río V, Beltrán E, et al. Successful optimization of adalimumab therapy in refractory uveitis due to Behçet’s disease. Ophthalmology. September 1, 2018;125(9):1444–1451. doi:10.1016/j.ophtha.2018.02.020.
  • Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behçet’s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. August 1, 2013;19(9):1833–1838. doi:10.1097/MIB.0b013e31828f19c9.
  • Hatemi I, Esatoglu SN, Hatemi G, et al. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet’s syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). April, 2016;95(16):e3348. doi:10.1097/MD.0000000000003348.
  • Travis SP, Czajkowski M, McGovern DP, et al. Treatment of intestinal Behçet’s syndrome with chimeric tumour necrosis factor α antibody. Gut. November 1, 2001;49(5):725–728. doi:10.1136/gut.49.5.725.
  • Kram MT, May LD, Goodman S, et al. Behçet’s ileocolitis: successful treatment with tumor necrosis factor–alpha antibody (infliximab) therapy. Dis Colon Rectum. January 1, 2003;46(1):118–121. doi:10.1007/s10350-004-6506-4.
  • Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of infliximab in patients with intestinal Behçet’s disease refractory to conventional medication. Internal Medicine. 2013;52(17):1855–1862. doi:10.2169/internalmedicine.52.0589.
  • Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies. J Gastroenterol. January 1, 2014;49(1):156–162. doi:10.1007/s00535-013-0872-4.
  • Díaz-Llopis M, Salom D, Garcia-de-vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. August 1, 2012;119(8):1575–1581. doi:10.1016/j.ophtha.2012.02.018.
  • Khraishi M, Stead D, Lukas M, et al. Biosimilars: a multidisciplinary perspective. Clin Ther. May 1, 2016;38(5):1238–1249. doi:10.1016/j.clinthera.2016.02.023.
  • Biosimilars of adalimumab. (2021). http://www.gabionline.net/Biosimilars/General/Biosimilars-of-adalimumab.
  • Jamshidi A, Gharibdoost F, Vojdanian M, et al. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. Arthritis Res Ther. December, 2017;19(1):168.
  • Zierhut M, Deuter C, Murray PI. Classification of uveitis–current guidelines. J-Classif Uveitis Curr Guidelines. Europ. Ophthal. Rev. 2007;00(00):77–8. doi: 10.17925/EOR.2007.00.00.77.
  • Tugal-Tutkun I. Behçet’s uveitis. Middle East Afr J Ophthalmol. October, 2009;16(4):219. doi:10.4103/0974-9233.58425.
  • Bawazeer A, Raffa LH, Nizamuddin. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm. June 1, 2010;18(3):226–232. doi:10.3109/09273948.2010.483314.
  • Ho M, Chen LJ, Sin HP, et al. Experience of using adalimumab in treating sight-threatening pediatric or adolescent Behçet’s disease-related uveitis. J Ophthalmic Inflamm Infect. December 1, 2019;9(1):14. doi:10.1186/s12348-019-0181-z.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.